|Registry of biomedical companies:
  [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [Z] 525 active entries
Phone: +49 30 84 17 88 0
Fax: +49 30 84 17 88 50
Stock symbol: MGN.FSE
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
MOLOGEN AG is a biopharmaceutical company located in Berlin and currently employs 44 people. The company specializes in the development of DNA-based therapeutics and vaccines against cancer and infectious diseases. The proprietary platform technologies MIDGE® and dSLIM® build the foundation for all business activities.
Founded in 1998, MOLOGEN was one of the first German biotechnology companies to go public. MOLOGEN AG shares are listed in the Prime Standard of Deutsche Börse (ISIN DE 0006637200).
Novel TLR9 Agonist dSLIM® (double Stem Loop ImmunoModulator): dumbbell-shaped molecule with two single-stranded loops that are connected by a double-stranded stem, consisting of only non-coding DNA without any chemical modification; action of dSLIM® molecule is mediated through binding to TLR9 and results in a broad activation of the immune system initiating a fast defensive reaction against infectious agents;
dSLIM®-based cancer medicine MGN1703 (CRC) currently in phase I; phase II planned for Q4/2009
MIDGE® (Minimalistic Immunogenically Defined Gene Expression): DNA-vector that exclusively contains the clinically relevant genetic information; MIDGE® features a linear DNA pattern and is covalently closed by single-stranded hairpin structures at both ends; hairpin tails may be attached with different molecules allowing for various applications (e.g. MIDGE®-Th1 vector induces improved cellular and humoral immune responses, therefore it is well suited for DNA vaccination);
preclinical development of MGN1331, a DNA vaccine against human Leishmaniasis, funded by the 7th Research Framework Programme of the EU
For more information about the company or the current status of development programs please visit: www.mologen.com
- - Research
Last update of this entry: July 20, 2009